Study of Novel Therapeutics for Acute Remedy of Colitis

Exclusion Criteria

• •History of uncontrolled hypertension with systolic BP \> 140 and systolic BP \> 90
• •Chronic kidney disease as defined by GFR \<55mL/min
• •Impaired hepatic function (transaminases elevated \> 2.5 x ULN) unless due to PSC
• •Evidence of C. difficile (Negative test result within 1 month is acceptable)
• •Infectious Colitis or drug induced colitis
• •Crohn's Disease or Indeterminate colitis
• •Decompensated liver disease
• •Patients who are pregnant or breastfeeding
• •Patients who have a confirmed malignancy or cancer within 5 years
• •Congenital or acquired immunodeficiencies
• •Other comorbidities including: Diabetes mellitus, systemic lupus
• •Participation in a therapeutic clinical trial in the preceding 30 days or simultaneously during this trial
• •Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease
• •Prohibited medications:
• •* Rinvoq (Upadacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation.
• •* Xeljanz (Tofacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation.
• •* Other Medications: Subjects will be excluded from this study if they stopped taking any other medications for ulcerative colitis within 8 weeks. If subjects have stopped taking the medication and their last dose was more than 8 weeks prior to enrollment, they will be eligible for participation.